| MORO-SIBILOT, Denis |
ELDERLY, NCT03977194: Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy |
|
|
| Active, not recruiting | 3 | 500 | Europe | Carboplatin, Paclitaxel, Atezolizumab | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer Metastatic | 12/24 | 12/26 | | |
COSTAR Lung, NCT04655976 / 2020-003433-37: Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy |
|
|
| Active, not recruiting | 3 | 758 | Europe, Canada, Japan, US, RoW | Cobolimab, Dostarlimab, Docetaxel | GlaxoSmithKline | Lung Cancer, Non-Small Cell | 04/25 | 10/25 | | |
NCT06095583: Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC) |
|
|
| Recruiting | 3 | 756 | Europe, US, RoW | Tifcemalimab injection, toripalimab injection, Placebo for Tifcemalimab, Placebo for toripalimab | Shanghai Junshi Bioscience Co., Ltd. | Limited-stage Small Cell Lung Cancer (LS-SCLC) | 07/27 | 07/29 | | |
| Terminated | 2 | 3 | Europe, US, RoW | KRT-232, navtemadlin | Kartos Therapeutics, Inc. | Small-cell Lung Cancer, Small Cell Lung Carcinoma, Small Cell Lung Cancer Extensive Stage, Small Cell Lung Cancer Recurrent | 08/22 | 08/22 | | |
ORBITAL, NCT04233021: Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation |
|
|
| Active, not recruiting | 2 | 57 | Europe | Osimertinib | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer Metastatic, Leptomeningeal Metastasis, Brain Metastases, EGFR Activating Mutation | 03/23 | 12/24 | | |
| Active, not recruiting | 2 | 50 | Europe | Durvalumab | Intergroupe Francophone de Cancerologie Thoracique, IFCT, AstraZeneca | Non-small Cell Lung Cancer Stage IV | 11/23 | 10/25 | | |
ORAKLE, NCT04111705: Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients with Advanced ALK-positive Non-small Cell Lung Cancer |
|
|
| Active, not recruiting | 2 | 23 | Europe | Lorlatinib | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer Metastatic | 01/25 | 01/25 | | |
| Recruiting | 2 | 119 | Europe | Encorafenib 75 MG, Binimetinib 15 MG | Intergroupe Francophone de Cancerologie Thoracique, IFCT, Pierre Fabre | Non Small Cell Lung Cancer, BRAF V600E | 12/24 | 03/26 | | |
|
NCT04621188: Lorlatinib After Failure of First-line TKI in Patients with Advanced ROS1-positive NSCLC (ALBATROS) |
|
|
| Recruiting | 2 | 84 | Europe | Lorlatinib | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer Metastatic | 03/25 | 01/26 | | |
| Active, not recruiting | 2 | 110 | Europe | Brigatinib 180 MG, ALUNBRIG, Carboplatin, Pemetrexed | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer, ALK Gene Mutation | 04/25 | 10/28 | | |
ADAPTABLE, NCT05781308: Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients with Advanced NSCLC Progressing After Immunotherapy & Chemotherapy |
|
|
| Active, not recruiting | 2 | 156 | Europe | Paclitaxel, Bevacizumab, Avastin, Atezolizumab, Tecentriq | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer | 09/25 | 06/26 | | |
TAXIO, NCT05856695: A Phase II Study Assessing the Efficacy of Etoposide Free Chemotherapy Plus Durvalumab (MEDI4736) in First Line Extensive Disease Small Cell Lung Cancer (SCLC) |
|
|
| Recruiting | 2 | 67 | Europe | Carboplatin + Paclitaxel + Durvalumab | Intergroupe Francophone de Cancerologie Thoracique | Small Cell Lung Cancer Extensive Stage | 02/26 | 02/28 | | |
| Active, not recruiting | 1/2 | 73 | Europe | PDC*lung01, Keytruda Injectable Product, Pembrolizumab, Alimta Injectable Product, Pemetrexed | PDC*line Pharma SAS | Non Small Cell Lung Cancer | 07/24 | 12/25 | | |
| Recruiting | 1/2 | 500 | Europe, Canada, Japan, US, RoW | Oral repotrectinib (TPX-0005), repotrectinib | Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd. | Locally Advanced Solid Tumors, Metastatic Solid Tumors | 02/28 | 02/28 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SHIELD-1, NCT03993873: Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET |
|
|
| Active, not recruiting | 1 | 95 | Europe, US, RoW | elzovantinib (TPX-0022) | Turning Point Therapeutics, Inc. | Advanced Solid Tumor, Metastatic Solid Tumors, MET Gene Alterations | 01/24 | 03/26 | | |
Argonaut, NCT05480865: SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation |
|
|
| Terminated | 1 | 28 | Europe, RoW | BBP-398, sotorasib | Navire Pharma Inc., a BridgeBio company, Amgen | Solid Tumor, Adult, Metastatic Solid Tumor, Metastatic NSCLC, Non Small Cell Lung Cancer | 08/24 | 08/24 | | |
| Recruiting | N/A | 900 | Europe | | Centre Leon Berard | Carcinoma, Non-Small-Cell Lung | 03/26 | 12/26 | | |
| Bylicki, Olivier |
PROMETHEE, NCT06646471: PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With Thoracic Malignancies |
|
|
| Recruiting | 4 | 500 | Europe | Bio-bank repository, Quality of Life (QoL), G-Code | Groupe Francais De Pneumo-Cancerologie | Non Small Cell Lung Cancer, Lung Cancer | 08/26 | 08/28 | | |
ELDERLY, NCT03977194: Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy |
|
|
| Active, not recruiting | 3 | 500 | Europe | Carboplatin, Paclitaxel, Atezolizumab | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer Metastatic | 12/24 | 12/26 | | |
PERSEE, NCT04547504: PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 % |
|
|
| Active, not recruiting | 3 | 349 | Europe | Pembrolizumab, Pembrolizumab and Chemotherapy drugs | University Hospital, Brest, Groupe Français de Pneumo-Cancérologie | Non-small-cell Lung Cancer | 12/25 | 12/25 | | |
ORBITAL, NCT04233021: Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation |
|
|
| Active, not recruiting | 2 | 57 | Europe | Osimertinib | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer Metastatic, Leptomeningeal Metastasis, Brain Metastases, EGFR Activating Mutation | 03/23 | 12/24 | | |
| Recruiting | 2 | 80 | Europe, RoW | Durvalumab with etoposide and Carboplatin/Cisplatin, MEDI4736 | Centre Leon Berard, Groupe Français de Pneumo-Cancérologie | Large Cell Neuroendocrine Carcinoma of the Lung | 09/28 | 09/29 | | |
REPOROS, NCT06552234: Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC |
|
|
| Not yet recruiting | 2 | 30 | Europe | Repotrectinib | Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer, Groupe Français de Pneumo-Cancérologie, Hospices Civils de Lyon | NSCLC Stage IV, NSCLC, Stage III | 09/31 | 09/31 | | |
| Active, not recruiting | 2 | 110 | Europe | Brigatinib 180 MG, ALUNBRIG, Carboplatin, Pemetrexed | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer, ALK Gene Mutation | 04/25 | 10/28 | | |
ADAPTABLE, NCT05781308: Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients with Advanced NSCLC Progressing After Immunotherapy & Chemotherapy |
|
|
| Active, not recruiting | 2 | 156 | Europe | Paclitaxel, Bevacizumab, Avastin, Atezolizumab, Tecentriq | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer | 09/25 | 06/26 | | |
TAXIO, NCT05856695: A Phase II Study Assessing the Efficacy of Etoposide Free Chemotherapy Plus Durvalumab (MEDI4736) in First Line Extensive Disease Small Cell Lung Cancer (SCLC) |
|
|
| Recruiting | 2 | 67 | Europe | Carboplatin + Paclitaxel + Durvalumab | Intergroupe Francophone de Cancerologie Thoracique | Small Cell Lung Cancer Extensive Stage | 02/26 | 02/28 | | |
NCT01817192: Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer |
|
|
| Recruiting | N/A | 1050 | Europe, US | Adjuvant Chemotherapy, Radiographic surveillance, 14-Gene Prognostic Assay | Razor Genomics, Encore Clinical | Non-Small Cell Lung Cancer | 05/27 | 05/27 | | |
MESO-IMMUNE, NCT05308966: Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab |
|
|
| Active, not recruiting | N/A | 200 | Europe | Data collection | Groupe Francais De Pneumo-Cancerologie, Bristol-Myers Squibb | Malignant Pleural Mesothelioma, Unresectable Malignant Neoplasm | 04/25 | 04/25 | | |
LUCSO, NCT03562052: Lung Cancer Screening in a Population Exposed to Occupational Lung Carcinogens |
|
|
| Recruiting | N/A | 6000 | Europe | | Centre Hospitalier Intercommunal Creteil, University Hospital, Bordeaux, Rennes University Hospital, Centre Hospitalier Régional et Universitaire de Brest, University Hospital, Caen, Centre Hospitalier Universitaire de Rouen, Direction Centrale du Service de Santé des Armées | Lung Cancer | 07/26 | 07/31 | | |
| Active, not recruiting | N/A | 413 | Europe | Quality of Life Questionnaire-Core 30 (QLQ-C30), Quality of Life Questionnaire-Lung Cancer 13 (QLQ-LC13), 5-level EuroQoL EQ5D (EQ5D-5L) | Groupe Francais De Pneumo-Cancerologie, AstraZeneca | Non-Small Cell Lung Cancer | 06/27 | 06/27 | | |
| Recruiting | N/A | 100 | Europe | RNAseq, DNA NGS | Groupe Francais De Pneumo-Cancerologie, Takeda | Non-small Cell Lung Cancer, ALK Gene Rearrangement Positive | 06/27 | 06/27 | | |
| ZOUAK, Ayoube |
ADAPTABLE, NCT05781308: Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients with Advanced NSCLC Progressing After Immunotherapy & Chemotherapy |
|
|
| Active, not recruiting | 2 | 156 | Europe | Paclitaxel, Bevacizumab, Avastin, Atezolizumab, Tecentriq | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer | 09/25 | 06/26 | | |
TAXIO, NCT05856695: A Phase II Study Assessing the Efficacy of Etoposide Free Chemotherapy Plus Durvalumab (MEDI4736) in First Line Extensive Disease Small Cell Lung Cancer (SCLC) |
|
|
| Recruiting | 2 | 67 | Europe | Carboplatin + Paclitaxel + Durvalumab | Intergroupe Francophone de Cancerologie Thoracique | Small Cell Lung Cancer Extensive Stage | 02/26 | 02/28 | | |
ROSIE, NCT06053099: A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19) |
|
|
| Recruiting | N/A | 300 | Europe | Plasma ctDNA, FFPE blocks | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer, EGFR Activating Mutation, EGFR DEL19, EGFR L858R | 10/31 | 10/31 | | |
